Category: Ongoing Trials

Home / Ongoing Trials

Categories

Advancing Alström Syndrome Treatment in China: Gene Therapy and Clinical Innovations at NCMC, Shanghai

Alström Syndrome (AS) Alström Syndrome (AS) is an ultra-rare genetic disorder characterized by a spectrum of progressive symptoms, including vision and hearing loss, obesity, type 2 diabetes, cardio...

Advancing Bardet-Biedl Syndrome Treatment in China: Gene Therapy and Clinical Innovations at NCMC, Shanghai

Bardet-Biedl Syndrome (BBS) Bardet-Biedl Syndrome (BBS) is a rare, multisystem genetic disorder characterized by symptoms such as retinal degeneration, obesity, polydactyly, kidney abnormalities, and...

Safety and Tolerability of VGB-R04 in Patients With Hemophilia B

Gene Therapy Trial VGB-R04 for Hemophilia B Patients in China Trial ID: NCT05152732Study Title: Safety and Tolerability of VGB-R04 in Patients With Haemophilia BSponsor: Institute of Hematology & ...

A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients

Gene Therapy Clinical Trial for Hemophilia B: ZS801 in China Trial ID: NCT05641610Study Title: A Non-Randomized, Open-Label, Dose-Escalation, Phase I/II Study to Evaluate the Safety, Tolerability, Kin...

A Clinical Study Evaluating the Safety and Efficacy of SKG0201 Injection in Patients With Spinal Muscular Atrophy Type 1

Clinical Trial Update: SKG0201 Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA 1) Trial ID: NCT06191354Study Title: A Multicenter, Open, Dose-Escalation Clinical Study Evaluating the Safety, Init...

GC101 Gene Therapy for Spinal Muscular Atrophy Type 1 – Phase I/II Clinical Trial

Gene Therapy for Spinal Muscular Atrophy Type 1 – Phase I/II Clinical Trial ClinicalTrials.gov Identifier: NCT05824169Sponsor: GeneCradle Inc.Study Title: Safety and Efficacy of GC101 Gene Therapy i...

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients

GC101 Gene Therapy for Spinal Muscular Atrophy Type 2 – Phase I/II Clinical Trial ClinicalTrials.gov Identifier: NCT05901987Sponsor: GeneCradle Inc.Study Title: Safety and Efficacy of GC101 Gene The...

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients

Phase III Trial: GC101 Gene Therapy for Type 2 Spinal Muscular Atrophy (SMA) ClinicalTrials.gov Identifier: NCT06971094Sponsor: GeneCradle Inc.Study Title: Safety and Efficacy Evaluation of GC101 Gen...

Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injection in the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) – Phase III ​

Phase III Trial: GC101 Gene Therapy for Type 2 Spinal Muscular Atrophy (SMA) ClinicalTrials.gov Identifier: NCT06971094Sponsor: GeneCradle Inc.Study Title: Safety and Efficacy Evaluation of GC101 Gen...

Gene Therapy for Wilson’s Disease in China

Gene Therapy for Wilson's Disease in China   Introduction Wilson’s disease is a rare genetic disorder that causes excessive copper accumulation in the liver, brain, and other vital organs. With...

We Are Online! Chat With Us!
Scan the code